Zhang H, et al. Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer. Drugs R D. Jun 1 2012;12(2):101-106.
The cardioprotective effects of salidroside were evaluated in 60 patients with breast cancer randomized to receive salidroside 600 mg/day or placebo (n=30 each) starting 1 week before and throughout chemotherapy. Evaluation measures included echocardiography, strain rate (SR) imaging, and plasma concentrations of reactive oxygen species (ROS) assessed at baseline and 7 days after each new epirubicin dose of 100 mg/m2. Although no differences in SR peak were observed at an epirubicin dose of 200 mg/m2, SR significantly normalized with salidroside vs placebo at 300 mg/m2 and 400mg/m2 of epirubicin. In addition, plasma concentrations of ROS were unchanged with salidroside, but significantly increased with placebo. The investigators concluded that salidroside may be protective against epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer.
Darbinyan V, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61(5):343-348.
Rhodiola rosea rhizome standardized extract SHR-5 was evaluated in 89 patients suffering from a current episode of mild to moderate depression in this double-blind placebo-controlled trial. Men and women aged 18-70 years with Hamilton Depression (HAMD) scores between 21 and 31 were randomized to receive either two 170-mg tablets daily (Group A: 340 mg/day total, n=31), two 170-mg tablets twice daily (Group B: 680 mg/day total, n=29), or placebo (Group C: n=29) for a 6-week period. Efficacy from total and specific subgroup HAMD scores with respect to depressive complaints was assessed on days 0 and 42 of the study period. In Groups A and B, overall depression, insomnia, emotional instability, and somatization, but not self-esteem, improved significantly following treatment compared with placebo. No serious side-effects were reported in any treatment group.
Shevtsov VA, et al. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine. Mar 2003;10(2-3):95-105.
In this study 161 cadets, ages 19 to 21 years, were randomized to receive either a single dose of standardized rhodiola extract, a single dose that was 50% stronger than the standardized dose, or placebo. Researchers found that the cadets who received rhodiola extract showed significant lowering of fatigue as measured by an antifatigue index compared with those on placebo. There was no difference in the index between the two dosage groups. However, these results cannot be generalized. More well-designed studies are warranted.